论文部分内容阅读
目的：评价和验证αＬ岩藻糖苷酶（ＡＦＵ）检测的临床意义。方法：连续监测法检测良恶性肝病的ＡＦＵ活性。结果：４７例肝癌（ＰＨＣ），６５例急性肝炎，５９例慢性肝炎，４８例肝硬变，４３例消化道肿瘤，６０例正常对照组；其测值（ｘ±ｓ）分别是１５．５５±７．３９、７．０４±２．８５、６．３５±２．４７、６．４４±２．６５、６．２８±２．５６和６．１５±１．４２Ｕ／Ｌ。ＰＨＣ组与其他各组间差异有显著性（Ｐ＜０．０１），其ＰＨＣ组阳性率为８０．８５％，ＡＦＵ法的特异性为９２．００％，与终点法比较，差异无显著性。结论：连续监测法检测ＡＦＵ速度快，精度高，是ＡＦＰ的良好互补手段，临床上有重要价值
Objective: To evaluate and verify the clinical significance of α-L-fucosidase (AFU) detection. METHODS: Continuous monitoring was used to detect AFU activity in benign and malignant liver diseases. Results: 47 cases of liver cancer (PHC), 65 cases of acute hepatitis, 59 cases of chronic hepatitis, 48 cases of cirrhosis, 43 cases of digestive tract tumors, 60 cases of normal control group; their measured values (x±s) were 15.55 ± 7.39, 7.04 ± 2.85, 6.35 ± 2.47, 6.44 ± 2.65, 6.28 ± 2.56, and 6.15 ± 1.42 U/L. There was a significant difference between PHC group and other groups (P<0.01). The positive rate in PHC group was 80.85%, and the specificity in AFU method was 92.00%. There was no significant difference compared with the endpoint method. . Conclusion: The continuous monitoring method for detecting AFU is fast and has high precision. It is a good complement to AFP and has clinically important value.